SCHEMBL6133963

SCHEMBL6133963

CC(C)n1nc(-c2c(OC3CCC3)nc(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.44

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.44
SRC P12931 1/20 0.38
ADORA2A P29274 15/20 0.37
ADORA1 P30542 14/20 0.37
HRH2 P25021 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134849 0.97 HRH3 (0.42) HRH3SRCADORA2AADORA1HRH2
SCHEMBL6133586 0.92 ADORA2A (0.39) HRH3ADORA2AADORA1
SCHEMBL6133778 0.87 ADORA2A (0.42) ADORA2AADORA1
SCHEMBL6133555 0.84 ADORA2A (0.41) ADORA2AADORA1
SCHEMBL6134113 0.83 ADORA2A (0.43) HRH3ADORA2AADORA1
SCHEMBL6133772 0.82 ADORA2A (0.40) HRH3ADORA2AADORA1
SCHEMBL5149115 0.81 HRH3 (0.42) HRH3SRC
SCHEMBL6133969 0.80 MGMT (0.41) SRCADORA2AADORA1
SCHEMBL6133677 0.80 ADORA2A (0.40) HRH3ADORA2AADORA1
SCHEMBL6135151 0.80 ADORA2A (0.40) HRH3SRCADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ASTELLAS PHARMA INC. (JP) 2005-02-24 US disclosed
WO-2003057689-A1 AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043315-A1 Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them ADORA2B, ADORA2A, ADORA1 HRH3 367/4885SRC 2622/4885ADORA2A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.